NLS Pharmaceutics Ltd.
13F holders, Q3 2025 (September 30)2holders −1
0new positions
1sold out
$1.83avg. 13F price*
At the end of Q3 2025, 2 institutions reported holding NLS Pharmaceutics Ltd. in their 13F filings, down 1 from Q2 2025. 0 opened new positions and 1 sold out. The largest holders were BVF Inc. ($263K) and UBS Group AG ($70).
- Company
- NLS Pharmaceutics Ltd.
- CUSIP
- H57830137
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $7K |
All 13F filers, Q2 2025 → Q3 2025: 17,454 shares sold, net −17,454 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| BVF Inc. | 0.01% | No change | 143,676 | $263K |
| UBS Group AG | 0.00% | Reduce -99.8% | 38 | $70 |
"% of holder's portfolio" is NLS PHARMACEUTICS LTD's weight in each manager's 13F, not the share of NLS Pharmaceutics Ltd. the manager owns.